Quintrio
Home

PHARMACEUTICAL PREPARATIONS

vTv Therapeutics Inc. Class A Common Stock

VTVT

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Last trade $17.51
Day change -$0.18 (-1.02%)
Day range $16.48 – $17.84
Volume 24,116
Market cap $71M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$70.96M
Price / earnings
—
Price / book
1.02×
Price / sales
1.93×
EV / sales
-0.17×
EV / EBITDA
0.56×

Profitability

Earnings per share
-$1.91
Return on assets
-9.77%
Return on equity
-11.02%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
11.19×
Quick ratio
11.19×
Cash ratio
10.99×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$21.73M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VTVT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$36.84M$0$0$0$0$17K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$36.84M$0$0$0$0$17K
Selling, general and administrative$4.9M$5.16M$4.6M$3.98M$3.68M$3.62M$3.67M$2.68M
Research and development$7.53M$8.77M$8.98M$3.91M$7.02M$4.1M$2.83M$2.23M
Total operating expenses$12.43M$13.93M$13.58M$8.02M$10.7M$7.72M$6.5M$4.9M
Operating income-$12.43M-$13.93M$23.26M-$8.02M-$10.7M-$7.72M-$6.5M-$4.88M
Interest expense$0$0$0-$1K-$5K$0$0$0
Income before taxes-$11.62M-$13.05M$24.13M-$7.14M-$10.35M-$7.38M-$6.22M-$4.44M
Income taxes$0$0$0$0$0$0$0$0
Net income-$11.62M-$13.05M$24.13M-$7.14M-$10.35M-$7.38M-$6.22M-$4.44M
Net income attributable to common shareholders-$11.62M-$13.05M$24.13M-$7.14M-$8.7M-$6.05M-$5.09M-$3.63M
EBITDA-$12.43M-$13.93M$23.26M-$8.02M-$10.7M-$7.72M-$6.49M-$4.86M
Basic earnings per share-$0.94-$1.05$1.94-$0.57-$1.08-$0.92-$0.77-$0.51
Diluted earnings per share-$0.94-$1.05$1.65-$0.57-$1.08-$0.92-$0.77-$0.51

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

iOnctura appoints Paul Sekhri as Chair of its Board of Directors

iOnctura, a clinical-stage precision oncology company, announced the appointment of Paul Sekhri as Chair of its Board of Directors. Sekhri brings over 35 years of life science executive experience and has led multiple biotech companies through commercialization. The appointment comes as iOnctura prepares for late-stage development of roginolisib, its lead PI3Kδ inhibitor candidate, with two randomized Phase II studies fully enrolled. Roginolisib has shown promising clinical signals including doubled overall survival in uveal melanoma compared to historical controls.

GlobeNewswire Inc.

vTv Therapeutics to Participate in September Investor Conferences

vTv Therapeutics announced that management will participate in two investor conferences in September 2026: the H.C. Wainwright 28th Annual Global Investment Conference on September 16 and the 5th Annual ROTH Healthcare Opportunities Conference on September 29. The company continues advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes, with its Phase 3 CATT1 trial expected to complete enrollment in Q3 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 21, 20231-for-40reverse split